Innovative analgesic continues to perform well in mid-stage testing

A new kind of pain medicine has performed well in a Phase II trial, according to data presented at the 16th Annual Pain Therapeutics Summit in Washington DC, USA.

Results from the RELIEF-DPN-1 study show that the novel oral therapy LX9211, an AAK1 inhibitor, was able to reduce symptoms such as burning pain and interference of pain in sleep, for people with diabetic neuropathy.

The candidate, which is under development by Texan company Lexicon Pharmaceuticals (Nasdaq: LXRX), was discovered using its proprietary Genome5000 program.